245
Views
1
CrossRef citations to date
0
Altmetric
Review

Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?

, , &
Pages 1033-1045 | Received 15 Jul 2016, Accepted 25 Aug 2016, Published online: 07 Sep 2016

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.21294.
  • Smolewski P, Witkowska M, Robak T. Treatment options for mantle cell lymphoma. Expert Opin Pharmacother. 2015;16:2497–2507. doi:10.1517/14656566.2015.1087507.
  • Lenz G, Staudt ML. Aggressive lymphomas. N Engl J Med. 2010;362:1417–1429. doi:10.1056/NEJMra0807082.
  • Mani A, Gelmann EP. The ubiquitin–proteasome pathway and its role in cancer. J Clin Oncol. 2005;23:4776–4789. doi:10.1200/JCO.2005.05.081.
  • Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369–381. doi:10.1038/nrc1881.
  • Chen L, Juszczynski P, Takeyama K, et al. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006;108:3428–3433. doi:10.1182/blood-2006-03-013821.
  • Flinn IW, Bartlett NL, Blum KA, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016;54:11–17. doi:10.1016/j.ejca.2015.10.005.
  • Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–551. doi:10.1056/NEJMoa1306220.
  • Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–926. DOI:10.1038/nm.3884
  • Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372:1430–1440. doi:10.1056/NEJMoa1501548.
  • Maddocks K, Christian B, Jaglowski S, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;125:242–248. doi:10.1182/blood-2014-08-597914.
  • Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203. doi:10.1182/blood-2016-03-707133.
  • Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5:1602–1609.
  • Blachly JS, Baiocchi RA. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol. 2014;167:19–32. doi:10.1111/bjh.13065.
  • Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398–3405. DOI:10.1182/blood-2013-11-537555
  • Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep. 2009;11:102–110.
  • Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053–4062. doi:10.1182/blood-2005-08-3434.
  • Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumour efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9:2276–2286. doi:10.1158/1535-7163.MCT-10-0338.
  • Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des. 2012;18:2766–2777.
  • Smith SM. Clinical development of mTOR inhibitors: a focus on lymphoma. Rev Recent Clin Trials. 2007;2:103–110.
  • Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829. DOI:10.1200/JCO.2008.20.7977
  • Hess G, Keller U, Scholz CW, et al. Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia. 2015;29:1695–1701. doi:10.1038/leu.2015.60.
  • Inwards DJ, Fishkin PA, LaPlant BR, et al. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol. 2014;25:2020–2024. doi:10.1093/annonc/mdu273.
  • Barnes JA, Jacobsen E, Feng Y, et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013;98:615–619. DOI:10.3324/haematol.2012.075184
  • O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–684. doi:10.1200/JCO.2005.02.050.
  • Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29:3389–3395. doi:10.1200/JCO.2010.32.1844.
  • Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383–6391. doi:10.1158/0008-5472.CAN-06-4086.
  • Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2000;18:1812–1823.
  • Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–3428. doi:10.1158/0008-5472.CAN-07-5836.
  • Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149–1159. DOI:10.1016/S1470-2045(10)70261-8
  • Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784. doi:10.1038/nrd2133.
  • Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:1198–1203. DOI:10.1200/JCO.2010.32.1398
  • Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10:387–402. doi:10.1038/nri2765.
  • Turner M, Schweighoffer E, Colucci F, et al. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. 2000;21:148–154.
  • Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230–2237. doi:10.1182/blood-2007-07-100115.
  • Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:3827–3834. doi:10.1182/blood-2009-12-255992.
  • Lamb DJ, Wollin SL, Schnapp A, et al. BI 1002494, a novel potent and selective oral spleen tyrosine kinase inhibitor, displays differential potency in human basophils and B cells. J Pharmacol Exp Ther. 2016;357:554–561. doi:10.1124/jpet.116.233155.
  • Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015;125:2336–2343. doi:10.1182/blood-2014-08-595934.
  • Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules. 2014;19:14304–14315. doi:10.3390/molecules190914304.
  • Vega GG, Avilés-Salas A, Chalapud JR, et al. P38 MAPK expression and activation predicts failure of response to CHOP in patients with diffuse large B-cell lymphoma. BMC Cancer. 2015 Oct 16;15:722. DOI:10.1186/s12885-015-1584-3.
  • Badar T, Cortes JE, Ravandi F, et al. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015;15:433–438.e2. doi:10.1016/j.clml.2015.02.018.
  • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134. doi:10.1056/NEJMc063190.
  • Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835–844. doi:10.1038/nrd2130.
  • Greenwald DR, Li H, Luger SM, et al. A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an Eastern Cooperative Oncology Group study (E1404). J Hematol Oncol. 2013;6(1):46. DOI:10.1186/1756-8722-6-46.
  • Maas A, Hendriks RW. Role of Bruton’s tyrosine kinase in B cell development. Dev Immunol. 2001;8:171–181.
  • Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94. DOI:10.1200/JCO.2012.42.7906
  • Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–287. doi:10.1111/j.1600-065X.2008.00754.x.
  • Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012;30:4161–4167. doi:10.1200/JCO.2012.42.5223.
  • Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406–3413. doi:10.1182/blood-2013-11-538546.
  • Gopal AK, Kahl BS, De Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018. DOI:10.1056/NEJMoa1314583
  • Horwitz S, Flinn I, Patel M, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ, γ, in patients with relapsed/refractory lymphoma. Chicago, IL: American Society of Clinical Oncology; 2013.
  • Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström’s macroglobulinemia. Clin Cancer Res. 2010;16:1033–1041. DOI:10.1158/1078-0432.CCR-09-1837
  • Guidetti A, Carlo-Stella C, Locatelli SL, et al. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. Clin Cancer Res. 2014; 20:5641–5651.
  • Oki Y, Fanale M, Romaguera J, et al. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015;171:463–470. doi:10.1111/bjh.13603.
  • Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347–5356. DOI:10.1200/JCO.2005.13.466
  • Smith SM, Besien K, Van Karrison T, et al. Temsirolimus has activity in non–mantle cell non-Hodgkin’s lymphoma subtypes: the University of Chicago phase II consortium. Jco. 2010;28:4740–4746. doi:10.1200/JCO.2010.29.2813.
  • Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25:341–347. doi:10.1038/leu.2010.226.
  • Rizzieri DE, Feldman E, DiPersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008;14:2756–2762. doi:10.1158/1078-0432.CCR-07-1372.
  • Nencioni A, Grünebach F, Patrone F, et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia. 2007;21:30–36. doi:10.1038/sj.leu.2404444.
  • Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520–525. doi:10.1093/annonc/mdn656.
  • Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:4293–4297. DOI:10.1200/JCO.2007.11.4207
  • Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:667–675. DOI:10.1200/JCO.2005.03.108
  • Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s macroglobulinemia. J Clin Oncol. 2009;27:120–126. doi:10.1200/JCO.2008.17.7865.
  • Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–953. doi:10.1056/NEJMoa1412096.
  • Evens AM, Hong F, Habermann TM, et al. Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): a randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). J Clin Oncol. 2016;34(suppl; abstr 7507).
  • Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:690–697. doi:10.1200/JCO.2010.31.1142.
  • Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012;18;4830.
  • Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111:3322–3330. doi:10.1182/blood-2007-09-078162.
  • Rai KR, Moore J, Wu J, et al. Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: five-year follow-up from a randomized phase III study [abstract]. J Clin Oncol. 2008;26:7008. DOI:10.1200/JCO.2007.15.2777
  • Pro B, Leber B, Smith M, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008;143:355–360. DOI:10.1111/j.1365-2141.2008.07353.x
  • Liang XS, Rogers AJ, Webber CL, et al. Developing gossypol derivatives with enhanced antitumor activity. Invest New Drugs. 1995;13:181–186. doi:10.1007/BF00873798.
  • Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137–1141.
  • Davids MS, Seymour JF, Gerecitano JF, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol. 2014;32(15_suppl):8522. ASCO Meeting Abstr.
  • O’Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166–173. doi:10.1200/JCO.2005.01.9679.
  • Olsen EA, Kim YH, Kuzel TM, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–3115. DOI:10.1200/JCO.2006.10.2434
  • Budde LE, Zhang MM, Shustov AR, et al. Phase I study of pulse high-dose vorinostat (v) plus rituximab (r), ifosphamide, carboplatin, and etoposide (ice) in patients with relapsed lymphoma. Br J Haematol. 2013;161:183–191. DOI:10.1111/bjh.12230.
  • Oki Y, Buglio D, Fanale M, et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013;19:6882–6890. DOI:10.1158/1078-0432.CCR-13-1906.
  • Tan D, Phipps C, Hwang WY, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2015;2:e326–333.
  • Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008;7:759–768. DOI:10.1158/1535-7163.MCT-07-2026.
  • Crump M, Andreadis C, Assouline S, et al. Treatment of relapsed or refractory non-Hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. J Clin Oncol. 2008;26((15)suppl. Abstract 8528). DOI:10.1200/JCO.2007.15.2777.
  • Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11. doi:10.1186/1756-8722-7-11.
  • Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:5404–5409. DOI:10.1200/JCO.2008.21.1169
  • Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–1627. DOI:10.1093/annonc/mdq626
  • Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145:344–349. doi:10.1111/j.1365-2141.2009.07626.x.
  • O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–1189. DOI:10.1200/JCO.2010.29.9024
  • Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199–4206. doi:10.1200/JCO.2013.49.0219.
  • Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77. doi:10.1016/S1470-2045(13)70510-2.
  • Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10:267–276. doi:10.1038/nrclinonc.2013.46.
  • Katz BZ, Herishanu Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leuk Lymphoma. 2014;55:999–1006. doi:10.3109/10428194.2013.828354.
  • Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410–1416. DOI:10.1182/blood-2015-06-651380.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.